RAS Inhibitor Is Not Associated With Cardiovascular Benefits in Patients Undergoing Hemodialysis in Japan-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

RAS Inhibitor Is Not Associated With Cardiovascular Benefits in Patients Undergoing Hemodialysis in Japan

Published:2017-08 Issue:4 Volume:21 Page:326-333
ISSN:1744-9979
Container-title:Therapeutic Apheresis and Dialysis
language:en
Short-container-title:Ther Apher Dial

Author:

Mizobuchi Masahide¹^ORCID,Ogata Hiroaki²,Onishi Yoshihiro³,Fukuma Shingo⁴^ORCID,Akizawa Tadao¹,Fukuhara Shunichi⁴

Affiliation:

1. Division of Nephrology, Department of Medicine; Showa University School of Medicine; Tokyo Japan

2. Department of Internal Medicine; Showa University Northern Yokohama Hospital; Yokohama Japan

3. Institute for Health Outcomes & Process Evaluation Research (iHope International); Kyoto Japan

4. Department of Epidemiology and Healthcare Research; Kyoto University Graduate School of Medicine; Kyoto Japan

Publisher

Wiley

Subject

Nephrology,Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1744-9987.12540/fullpdf

Reference47 articles.

1. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention;Sarnak;Circulation,2003

2. Excerpts from the United States Renal Data System 2007 annual data report;Collins;Am J Kidney Dis,2008

3. US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States;Saran;Am J Kidney Dis,2015

4. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol;Dahlof;Lancet,2002

5. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators;Yusuf;N Engl J Med,2000

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of aspirin on cardiovascular events in patients undergoing hemodialysis with hyperphosphatemia: A post hoc analysis of the LANDMARK trial;Therapeutic Apheresis and Dialysis;2024-03-12

2. Effect of renin–angiotensin system inhibitors on cardiovascular events in hemodialysis patients with hyperphosphatemia: A post hoc analysis of the LANDMARK trial;Therapeutic Apheresis and Dialysis;2023-11-03

3. Renin-Angiotensin-Aldosterone System (RAS) Inhibitors May Suppress the Prevalence of Peripheral Arterial Disease (PAD) in Elderly, Chronic Hemodialysis Patients;Cureus;2022-05-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3